¼¼°èÀÇ ÈÞ´ë¿ë Áø´Ü ±â±â ½ÃÀå
Portable Diagnostic Devices
»óǰÄÚµå : 1793734
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 296 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,183,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,550,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÈÞ´ë¿ë Áø´Ü ±â±â ¼¼°è ½ÃÀåÀº 2030³â±îÁö ¹Ì±¹¿¡¼­ 1,115¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 697¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÈÞ´ë¿ë Áø´Ü ±â±â ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 8.1%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 1,115¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ºÎÀΰú ¿ëµµ´Â CAGR 10.0%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á±îÁö 339¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼øÈ¯±â ¿ëµµ ºÎ¹®ÀÇ ¼ºÀåÀº ºÐ¼® ±â°£ µ¿¾È 9.1%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 190¾ï ´Þ·¯, Áß±¹Àº CAGR 13.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÈÞ´ë¿ë Áø´Ü ±â±â ½ÃÀåÀº 2024³â¿¡ 190¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 243¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 13.0%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 4.0%¿Í 7.9%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÈÞ´ë¿ë Áø´Ü ±â±â ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Point-of-Care IntelligenceÀÇ ÀçÁ¤ÀÇ: ÈÞ´ë¿ë Áø´Ü µµ±¸°¡ ºÐ»êÇü ÇコÄɾîÀÇ »õ·Î¿î ½Ã´ë¸¦ ¿©´Â ÀÌÀ¯

ÈÞ´ë¿ë Áø´Ü ±â±â°¡ POC °Ë»ç ¹æ½ÄÀ» ¾î¶»°Ô ¹Ù²Ü °ÍÀΰ¡?

ÈÞ´ë¿ë Áø´Ü ±â±â´Â º´¿ø, ÀÀ±Þ½Ç, Ŭ¸®´Ð, ¿ø°ÝÁö µî ±âÁ¸ °Ë»ç½Ç ȯ°æ ÀÌ¿ÜÀÇ Àå¼Ò¿¡¼­ ½Ç½Ã°£ ÀÇ·á °Ë»ç¸¦ °¡´ÉÇÏ°Ô ÇÏ¿© º¸´Ù ½Å¼ÓÇÑ ÀÓ»óÀû ÆÇ´ÜÀ» Áö¿øÇÕ´Ï´Ù. ÀÌ ¼ÒÇü ÇÚµåÇïµå ¶Ç´Â īƮ ÀåÂøÇü ½Ã½ºÅÛÀº Áúº´ÀÇ Á¶±â ¹ß°ß, ½Å¼ÓÇÑ ºÐ·ù ¹× Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µÀ» ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù. ÁÖ¿ä Ä«Å×°í¸®¿¡´Â Ç÷´ç ¸ð´ÏÅÍ, ÈÞ´ë¿ë ÃÊÀ½ÆÄ, ½ÉÀüµµ ÀåÄ¡, ¸Æ¹Ú »ê¼Ò ÃøÁ¤±â, ½Å¼Ó Ç׿ø °Ë»ç ŰƮ, °¨¿° ºÐ¼®±â, ´ÙÁß ¸Å°³ º¯¼ö ÀåÄ¡ µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ¸¸¼ºÁúȯ(´ç´¢, ½ÉÇ÷°üÁúȯ µî), °¨¿°º´(COVID-19, ¸»¶ó¸®¾Æ, HIV µî), ÀÀ±ÞÁúȯ(³úÁ¹Áß, ¿Ü»ó, ½ÉÁ¤Áö µî)ÀÇ ½Å¼ÓÇÑ Áø´ÜÀ» µ½½À´Ï´Ù. ³ôÀº Á¶ÀÛ¼º, È޴뼺, ¿¬°á¼ºÀº ºÐ»êÇü °Ë»ç, Áö¿ª ÀÇ·á, ¸ð¹ÙÀÏ Áø´Ü¿¡¼­ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. Àα¸ °í·ÉÈ­, ¸¸¼ºÁúȯÀÇ È®»ê, ÆÒµ¥¹Í ´ëºñ µî ¼¼°è º¸°Ç ºÐ¾ßÀÇ µµÀü°úÁ¦´Â ÇコÄÉ¾î ½Ã½ºÅÛ¿¡ È®Àå °¡´ÉÇÏ°í ¼³Ä¡ ¸éÀûÀÌ ÀûÀº Áø´Ü ¼Ö·ç¼ÇÀ» ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. ÈÞ´ë¿ë Áø´Ü µµ±¸´Â Àû½Ã¿¡ Ä¡·á °³ÀÔÀ» °¡´ÉÇÏ°Ô Çϰí, ÀÔ¿øÀ²À» ³·Ã߸ç, ÀÚ¿øÀÌ Ç³ºÎÇÑ È¯°æ°ú ÀÚ¿øÀÌ ºÎÁ·ÇÑ È¯°æ ¸ðµÎ¿¡¼­ ±¸Ã¼ÀûÀÎ °á°ú¸¦ °¡Á®¿É´Ï´Ù.

µµÀÔÀÌ °¡¼ÓÈ­µÇ°í ÀÖ´Â ÇコÄɾî ȯ°æ°ú ÀÓ»ó »ç¿ë »ç·Ê´Â?

ÀÏÂ÷ Áø·á ¹× ÀÀ±Þ½ÇÀº ÈÞ´ë¿ë Áø´Ü ±â±âÀÇ ÇÙ½É »ç¿ëÀÚÀÔ´Ï´Ù. ÀÌ·¯ÇÑ È¯°æ¿¡¼­ ħ´ë ¿·¿¡¼­ÀÇ ½Å¼ÓÇÑ Áø´ÜÀº ´ë±â ½Ã°£À» ´ÜÃàÇϰí, Áï°¢ÀûÀÎ °³ÀÔÀ» °¡´ÉÇÏ°Ô Çϸç, ȯÀÚÀÇ Ã³¸® ´É·ÂÀ» Çâ»ó½Ãŵ´Ï´Ù. ±¸±Þ´ë¿øÀ̳ª À̵¿ ÀÇ·áÆÀ¿¡¼­´Â ¼ÒÇü ÃÊÀ½ÆÄ³ª ½ÉÀüµµ ¸ð´ÏÅ͸¦ »ç¿ëÇÏ¿© º´¿ø Àü ¼±º°À» Çϰí, ¸¹Àº °æ¿ì Áï½Ã ´ëÀÀÇÒ ¼ö ÀÖµµ·Ï º´¿ø ÁöÈÖ ¼¾ÅÍ¿¡ µ¥ÀÌÅ͸¦ Àü¼ÛÇÕ´Ï´Ù. Áö¹æ Áø·á¼Ò³ª ÀÚ¿øÀÌ ºÎÁ·ÇÑ Áö¿ª¿¡¼­´Â Á¦ÇÑµÈ °Ë»ç½Ç Á¢±Ù¼ºÀ» ÇØ°áÇϱâ À§ÇØ ÇöÀå Áø·á ±â±â¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. ¹èÅ͸®·Î ÀÛµ¿µÇ´Â ºÐ¼®±â³ª ½º¸¶Æ®Æù¿¡ ³»ÀåµÈ ¸®´õ±â¸¦ ÅëÇØ ÇöÀå¿¡¼­ Áúº´ °ËÁø, »êÀü ¸ð´ÏÅ͸µ, ¿¹¹æÁ¢Á¾ ÃßÀûÀÌ °¡´ÉÇÕ´Ï´Ù. WHO, USAID, NGO°¡ ÀÚ±ÝÀ» Áö¿øÇÏ´Â ¼¼°èº¸°ÇÇÁ·Î±×·¥(World Health Program)Àº °¨¿°º´ °¨½Ã¿Í ¸ðÀÚº¸°Ç¿¡ ´ëÀÀÇϱâ À§ÇØ ÀÌ·¯ÇÑ ±â±â¸¦ µµÀÔÇϰí ÀÖ½À´Ï´Ù.

¼ÒºñÀÚ ÇコÄɾî¿Í Ȩ ÇコÄÉ¾î ºÐ¾ß´Â ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. °íÇ÷¾Ð, ´ç´¢º´, COPD µî ¸¸¼ºÁúȯÀ» ¾Î°í Àִ ȯÀÚµéÀº »ýü ÆÄ¶ó¹ÌÅ͸¦ ÃßÀûÇϱâ À§ÇØ ÈÞ´ë¿ë ¸ð´ÏÅ͸¦ »ç¿ëÇϰí ÀÖ½À´Ï´Ù. ³ëÀÎÀ̳ª °£º´ÀÎÀº µðÁöÅÐ Çコ Ç÷§Æû°ú µ¿±âÈ­µÇ´Â ºí·çÅõ½º Áö¿ø ±â±â¸¦ »ç¿ëÇÏ¿© ¿ø°ÝÁø·á ¹× µ¿Ç⠺м®À» Çϰí ÀÖ½À´Ï´Ù. ¼Ò¸ÅÁ¡ÀÇ Å°¿À½ºÅ© ´Ü¸»±â³ª ¿ø°ÝÀÇ·á ŰƮ¿¡´Â ¼­ºñ½º ¾ÆÅ°ÅØÃ³ÀÇ ÀϺηΠÈÞ´ë¿ë Áø´Ü µµ±¸°¡ Æ÷ÇԵǾî ÀÖ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù.

Ä¿³ØÆ¼ºñƼ, AI, µð¹ÙÀ̽º ¼ÒÇüÈ­ÀÇ Çõ½ÅÀº Áø´ÜÀ» ¾î¶»°Ô ¹ßÀü½Ã۰í Àִ°¡?

±â¼úÀû ¼ö·ÅÀÌ ÈÞ´ë¿ë Áø´Ü ±â±âÀÇ Â÷¼¼´ë Çõ½ÅÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÷´Ü ¼¾¼­, ¸¶ÀÌÅ©·ÎÀ¯Ã¼°øÇÐ, ·¦¿ÂĨ Ç÷§Æû, ¹ÙÀÌ¿À¼¾¼­´Â ½ÇÇè½Ç ¼öÁØÀÇ ºÐ¼®À» ÇÚµåÇïµå ÇüÅ·Π¼ÒÇüÈ­Çϰí ÀÖ½À´Ï´Ù. ÀÌ ÀåÄ¡´Â ÀÌÁ¦ ¸ÖƼÇ÷º½º °Ë»ç¸¦ Áö¿øÇÏ¿© ´ÜÀÏ »ùÇÿ¡¼­ ¿©·¯ ¹ÙÀÌ¿À¸¶Ä¿¸¦ µ¿½Ã¿¡ °ËÃâÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ½º¸¶Æ® Áø´Ü ±â±â´Â ¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼Ç, Ŭ¶ó¿ìµå Ç÷§Æû, EHR°ú ÅëÇÕµÇ¾î ½Ç½Ã°£ ºÐ¼®, ÀÚµ¿ ÇØ¼®, ȯÀÚ º´·Â »ó°ü°ü°è¸¦ Á¦°øÇÕ´Ï´Ù. AI¿Í ¸Ó½Å·¯´× ¾Ë°í¸®ÁòÀº ÀÚµ¿ ½ÉÀüµµ ºÐ¼®, ÇÚµåÇïµå ÃÊÀ½ÆÄ¸¦ ÅëÇÑ ¿µ»ó ±â¹Ý Áø´Ü, Ȱ·Â¡ÈÄ ¸ð´ÏÅ͸µÀÇ Ãß¼¼ ¿¹ÃøÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

ºí·çÅõ½º, Wi-Fi ¶Ç´Â ¼¿·ê·¯ ³×Æ®¿öÅ©¸¦ ÅëÇÑ ¹«¼± µ¥ÀÌÅÍ Àü¼ÛÀº ÀÇ»ç ¹× °£º´ÀΰúÀÇ ¿øÈ°ÇÑ Ä¿¹Â´ÏÄÉÀ̼ÇÀ» º¸ÀåÇÕ´Ï´Ù. ¿ø°ÝÀÇ·á Ç÷§Æû°úÀÇ ±â±â »óÈ£ ¿î¿ë¼ºÀº ¸¸¼ºÁúȯ °ü¸® ¹× ±Þ¼º±â ÀÌÈÄ Ä¡·á ¸ðµ¨¿¡ ÀÖ¾î ÇÙ½ÉÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ÇöÀç´Â À½¼º ¾È³», ´Ù±¹¾î ÀÎÅÍÆäÀ̽º, Ã˰¢ Çǵå¹éÀ» Á¦°øÇϰí Á¢±Ù¼ºÀ» ³ôÀÌ°í »ç¿ëÀÚ ¿À·ù¸¦ ÁÙÀÌ´Â ±â±âµéµµ ÀÖ½À´Ï´Ù. ¹èÅ͸® ¼ö¸í, °ß°íÇÑ µðÀÚÀÎ, ȯ°æ º¸È£ ±â´É(¹æ¼ö, ¹æÁø µî), ÇöÀå ¹èÆ÷¸¦ À§ÇØ °­È­µÈ ¹èÅ͸® ¼ö¸í, °ß°íÇÑ µðÀÚÀÎ, ȯ°æ º¸È£ ±â´É. ¶ÇÇÑ, Á¦Á¶¾÷ü´Â ½Å¼ÓÇÑ ±³Á¤, Á÷°üÀûÀÎ UX µðÀÚÀÎ, ISO, CE, FDA Ç¥ÁØ¿¡ ´ëÇÑ ±ÔÁ¦ ´ëÀÀ¿¡ ÁßÁ¡À» µÎ¾î ÀÓ»ó¿¡¼­ÀÇ ½Å·Ú¼º°ú äÅÃÀ» º¸ÀåÇÕ´Ï´Ù.

ÈÞ´ë¿ë Áø´Ü ±â±âÀÇ ¼¼°è ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ½ÃÀå ¿äÀÎÀº ¹«¾ùÀΰ¡?

ÈÞ´ë¿ë Áø´Ü ±â±â ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ÇコÄɾîÀÇ ºÐ»êÈ­, °í·ÉÈ­, Á¶±â Áø´Ü°ú ¿¹¹æÀǷḦ Áß½ÃÇÏ´Â °¡Ä¡ ±â¹Ý ÄÉ¾î ¸ðµ¨·ÎÀÇ ÀüȯÀÔ´Ï´Ù. ƯÈ÷, °Ë»ç½Ç ÀÎÇÁ¶ó°¡ Á¦ÇÑÀûÀ̰ųª °á°ú µµÃâ±îÁöÀÇ ½Ã°£ÀÌ ¸Å¿ì Áß¿äÇÑ ´Ù¾çÇÑ ÀÇ·á ÇöÀå¿¡¼­ ½Å¼ÓÇϰí Á¤È®Çϸç È®Àå °¡´ÉÇÑ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ¼ºÀåÀÇ ÇÙ½É ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÆÒµ¥¹ÍÀ¸·Î ÀÎÇÑ ÇコÄɾîÀÇ ±¸Á¶Àû º¯È­´Â POC Áø´Ü¾àÀÇ Ã¤ÅÃÀ» Å©°Ô °¡¼ÓÈ­Çß½À´Ï´Ù. Áý´Ü °ËÁø ÇÁ·Î±×·¥, µå¶óÀÌºê ½º·ç Ŭ¸®´Ð, °¡Á¤¿ë °Ë»ç ŰƮ´Â ´ë±Ô¸ð °Ç°­ À§±â¿¡ ´ëÀÀÇÏ´Â ÈÞ´ë¿ë ¼Ö·ç¼ÇÀÇ È¿°ú¸¦ ÀÔÁõÇß½À´Ï´Ù. À̸¦ ÅëÇØ COVID-19 ÀÌÈÄ¿¡µµ ¸ð¹ÙÀÏ Áø´Ü¾à¿¡ Áö¼ÓÀûÀ¸·Î ÅõÀÚÇÒ ¼ö ÀÖ´Â ±æÀ» ¿­¾ú½À´Ï´Ù.

POC °Ë»ç¸¦ Áö¿øÇÏ´Â Á¤Ã¥Àû °³Çõ°ú »óȯ ¸ðµ¨µµ Á¢±Ù¼ºÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. ¸¹Àº Áö¿ª¿¡¼­ Á¤ºÎ´Â ±¹°¡ °ËÁø ÇÁ·Î±×·¥ÀÇ ÀÏȯÀ¸·Î ÀÏÂ÷ Áø·á¼Ò ¹× ³óÃÌ Áö¿ª ÀÇ·áÁø¿¡°Ô ÈÞ´ë¿ë Áø´Ü ±â±â¸¦ µµÀÔÇÒ ¼ö ÀÖµµ·Ï Àμ¾Æ¼ºê¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ½º¸¶Æ®Æù ¿¬µ¿Çü ÀåÄ¡¿Í °°Àº ¼ÒºñÀÚ ÀüÀÚ±â±â¿Í Áø´Ü¾àÀÇ À¶ÇÕÀº ÀÓ»ó ÇöÀå°ú °³ÀÎ °Ç°­ »ýŰèÀÇ °£±ØÀ» ¸Þ¿ì°í ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀÌ ºÐ»êÈ­, Àú°¡È­, µðÁöÅÐ ÅëÇÕÀ» Áß½ÃÇÏ´Â °¡¿îµ¥, ÈÞ´ë¿ë Áø´Ü ±â±â´Â ÀÓ»ó, Áö¿ª»çȸ, °³ÀÎ °Ç°­ ȯ°æ Àü¹Ý¿¡ °ÉÃÄ ÇʼöÀûÀÎ Á¸Àç°¡ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ½ÃÀåÀº ¼ÒÇüÈ­, AI, µ¥ÀÌÅÍ ±â¹Ý Ä¡·áÀÇ È¹±âÀûÀÎ ¹ßÀüÀ¸·Î ÀÎÇØ °ßÁ¶ÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

ºÎ¹®

¿ëµµ(ºÎÀΰú ¿ëµµ, ¼øÈ¯±â ¿ëµµ, ¼ÒÈ­±â ¿ëµµ, ºñ´¢±â ¿ëµµ, ½Å°æ ¿ëµµ, È£Èí±â ¿ëµµ, Á¤Çü¿Ü°ú ¿ëµµ, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(º´¿ø¡¤Áø·á¼Ò ÃÖÁ¾ ¿ëµµ, Áø´Ü ¼¾ÅÍ ÃÖÁ¾ ¿ëµµ, ÀçÅÃÀÇ·á ÇöÀå ÃÖÁ¾ ¿ëµµ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Portable Diagnostic Devices Market to Reach US$111.5 Billion by 2030

The global market for Portable Diagnostic Devices estimated at US$69.7 Billion in the year 2024, is expected to reach US$111.5 Billion by 2030, growing at a CAGR of 8.1% over the analysis period 2024-2030. Gynecology Application, one of the segments analyzed in the report, is expected to record a 10.0% CAGR and reach US$33.9 Billion by the end of the analysis period. Growth in the Cardiology Application segment is estimated at 9.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$19.0 Billion While China is Forecast to Grow at 13.0% CAGR

The Portable Diagnostic Devices market in the U.S. is estimated at US$19.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$24.3 Billion by the year 2030 trailing a CAGR of 13.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 7.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.

Global Portable Diagnostic Devices Market - Key Trends & Drivers Summarized

Redefining Point-of-Care Intelligence: Why Portable Diagnostics Are Powering a New Era in Decentralized Healthcare

How Are Portable Diagnostic Devices Changing the Face of Point-of-Care Testing?

Portable diagnostic devices are enabling real-time medical testing outside of traditional laboratory settings, empowering faster clinical decision-making across hospitals, emergency services, clinics, and remote field applications. These compact, handheld or cart-mounted systems facilitate early detection, rapid triaging, and continuous monitoring of diseases-streamlining workflows while reducing diagnostic delays. Key categories include blood glucose monitors, handheld ultrasound, ECG machines, pulse oximeters, rapid antigen test kits, infectious disease analyzers, and multiparameter devices. These technologies support rapid diagnostics for chronic diseases (like diabetes and cardiovascular disorders), infectious diseases (such as COVID-19, malaria, HIV), and emergency conditions (stroke, trauma, cardiac arrest). Their high usability, portability, and connectivity are pivotal in decentralized testing, rural healthcare, and mobile diagnostics. Global health challenges, including aging populations, chronic disease prevalence, and pandemic preparedness, are pushing healthcare systems toward scalable, low-footprint diagnostic solutions. Portable diagnostics allow timely treatment interventions and reduce hospitalization rates-delivering tangible outcomes for both resource-rich and resource-constrained environments.

Which Healthcare Environments and Clinical Use Cases Are Accelerating Adoption?

Primary care settings and emergency departments are core users of portable diagnostic devices. In these environments, rapid diagnostics at the bedside reduce waiting times, enable on-the-spot interventions, and improve patient throughput. Paramedics and mobile health units use compact ultrasound and ECG monitors to provide pre-hospital triage, often transmitting data to hospital command centers for immediate action. Rural clinics and low-resource geographies heavily rely on point-of-care devices to address limited laboratory access. Battery-powered analyzers and smartphone-integrated readers enable disease screening, prenatal monitoring, and immunization tracking in field settings. Global health programs funded by WHO, USAID, and NGOs are deploying such devices to address infectious disease surveillance and maternal-child health.

The consumer and home healthcare segment is growing rapidly. Patients with chronic diseases such as hypertension, diabetes, and COPD are adopting portable monitors to track vital parameters. Elderly individuals and caregivers are using Bluetooth-enabled devices that sync with digital health platforms for remote consultation and trend analysis. Retail health kiosks and telemedicine kits often include portable diagnostic tools as part of their service architecture.

How Are Innovations in Connectivity, AI, and Device Miniaturization Advancing Diagnostics?

Technological convergence is driving next-generation innovation in portable diagnostic devices. Advanced sensors, microfluidics, lab-on-chip platforms, and biosensors are miniaturizing laboratory-grade analysis into handheld formats. Devices now support multiplex testing, allowing simultaneous detection of multiple biomarkers from a single sample-enhancing diagnostic yield and cost-efficiency. Smart diagnostics are integrating with mobile applications, cloud platforms, and EHRs to provide real-time analytics, automated interpretation, and patient history correlation. AI and machine learning algorithms are enabling automated ECG analysis, image-based diagnosis from handheld ultrasound, and trend prediction in vital sign monitoring.

Wireless data transmission through Bluetooth, Wi-Fi, or cellular networks ensures seamless communication with physicians and caregivers. Device interoperability with telehealth platforms is central to chronic disease management and post-acute care models. Some devices now offer voice guidance, multilingual interfaces, and haptic feedback to enhance accessibility and reduce user error. Battery life, rugged design, and environmental protection features (e.g., water resistance, dustproofing) are being enhanced for field deployment. Manufacturers are also focusing on faster calibration, intuitive UX design, and regulatory compliance with ISO, CE, and FDA standards to ensure clinical credibility and adoption.

What Are the Key Market Catalysts Driving Portable Diagnostic Device Growth Globally?

The growth in the portable diagnostic devices market is driven by healthcare decentralization, aging demographics, and the shift toward value-based care models that emphasize early diagnosis and preventive health. A core growth driver is the rising demand for rapid, accurate, and scalable diagnostics in diverse care settings-particularly where laboratory infrastructure is limited or time-to-result is critical. Pandemic-induced structural changes in healthcare have significantly accelerated POC diagnostics adoption. Mass screening programs, drive-through clinics, and at-home test kits demonstrated the efficacy of portable solutions in handling large-scale health crises. This has paved the way for sustained investment in mobile diagnostics beyond COVID-19.

Policy reforms and reimbursement models supporting POC testing are also expanding access. In many regions, governments are incentivizing primary care clinics and rural health workers to adopt portable diagnostics as part of national screening programs. The convergence of diagnostics with consumer electronics, such as smartphone-linked devices, is bridging the gap between clinical settings and personal health ecosystems. As health systems focus on decentralization, affordability, and digital integration, portable diagnostic devices are expected to become indispensable across clinical, community, and personal health settings. The market is poised for robust expansion, driven by breakthroughs in miniaturization, AI, and data-driven care.

SCOPE OF STUDY:

The report analyzes the Portable Diagnostic Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Gynecology Application, Cardiology Application, Gastrointestinal Application, Urology Application, Neurology Application, Respiratory Application, Orthopedics Application, Other Applications); End-Use (Hospitals & Clinics End-Use, Diagnostic Centers End-Use, Homecare Settings End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â